Preclinical and clinical pharmacology of alcohol dependence

Tambour, Sophie; Quertemont, Etienne

doi:10.1111/j.1472-8206.2006.00459.x

Request a copy

Article (Scientific journals)

Preclinical and clinical pharmacology of alcohol dependence

Tambour, Sophie; Quertemont, Etienne

2007 • In Fundamental and Clinical Pharmacology, 21 (1), p. 9-28

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/1471

DOI
10.1111/j.1472-8206.2006.00459.x

PubMed
17227441

Files (2)Send to Details Statistics Bibliography Similar publications

Files

Full Text

FCP_Quertemont_2007.pdf

Publisher postprint (681.68 kB)

Request a copy

Annexes

FCP_Quertemont_2007_erratum.pdf

Publisher postprint (429.2 kB)

Erratum

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

alcohol; dependence; pharmacotherapy; relapse prevention; treatment

Abstract :

[en] In recent years, advances in neuroscience led to the development of new medications to treat alcohol dependence and especially to prevent alcohol relapse after detoxification. Whereas the earliest medications against alcohol dependence were fortuitously discovered, recently developed drugs are increasingly based on alcohol's neurobiological mechanisms of action. This review discusses the most recent developments in alcohol pharmacotherapy and emphasizes the neurobiological basis of anti-alcohol medications. There are currently three approved drugs for the treatment of alcohol dependence with quite different mechanisms of action. Disulfiram is an inhibitor of the enzyme aldehyde dehydrogenase and acts as an alcohol-deterrent drug. Naltrexone, an opiate antagonist, reduces alcohol craving and relapse in heavy drinking, probably via a modulation of the mesolimbic dopamine activity. Finally, acamprosate helps maintaining alcohol abstinence, probably through a normalization of the chronic alcohol-induced hyperglutamatergic state. In addition to these approved medications, many other drugs have been suggested for preventing alcohol consumption on the basis of preclinical studies. Some of these drugs remain promising, whereas others have produced disappointing results in preliminary clinical studies. These new drugs in the field of alcohol pharmacotherapy are also discussed, together with their mechanisms of action.

Research center :

Centre de Neurosciences Cognitives et Comportementales - ULiège

Disciplines :

Neurosciences & behavior
Pharmacy, pharmacology & toxicology
Psychiatry

Author, co-author :

Tambour, Sophie ; Université de Liège - ULiège > Département des sciences cognitives > Neuroscience comportementale et psychopharmacologie expér.

Quertemont, Etienne ; Université de Liège - ULiège > Département des sciences cognitives > Psychologie quantitative

Language :

English

Title :

Preclinical and clinical pharmacology of alcohol dependence

Publication date :

2007

Journal title :

Fundamental and Clinical Pharmacology

ISSN :

0767-3981

eISSN :

1472-8206

Publisher :

Blackwell Science, Oxford, United Kingdom

Volume :

Issue :

Pages :

9-28

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]

Available on ORBi :

since 28 November 2008

Statistics

Number of views

104 (11 by ULiège)

Number of downloads

4 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Grant B.F. Alcohol consumption, alcohol abuse and alcohol dependence. The United States as an example. Addiction (1994) 89 1357-1365.
Boffetta P., Hashibe M. Alcohol and cancer. Lancet Oncol. (2006) 7 149-156.
Harper C., Matsumoto I. Ethanol and brain damage. Curr. Opin. Pharmacol. (2005) 5 73-78.
West J.R., Chen W.J., Pantazis N.J. Fetal alcohol syndrome: the vulnerability of the developing brain and possible mechanisms of damage. Metab. Brain Dis. (1994) 9 291-322.
Willner I.R., Reuben A. Alcohol and the liver. Curr. Opin. Gastroenterol. (2005) 21 323-330.
Spanagel R., Mann K.F. Future perspectives on relapse prevention, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 217-226.
Diagnostic and statistical manual of mental disorders (DSM-IV-TR), 4th edn, text revision, American Psychiatric Association, Washington, DC, 2000, pp. 212-214.
Lovinger D.M., Crabbe J.C. Laboratory models of alcoholism: treatment target identification and insight into mechanisms. Nat. Neurosci. (2005) 8 1471-1480.
Edwards G. History of prevention of relapse, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 1-11.
Chin J.H., Goldstein D.B. Membrane-disordering action of ethanol. Variation with membrane cholesterol content and depth of the spin label probe. Mol. Pharmacol. (1981) 19 425-431.
Harris R.A. Ethanol actions on multiple ion channels: which are important? Alcohol. Clin. Exp. Res. (1999) 23 1563-1570.
Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J. Psychiatry Neurosci. (2003) 28 263-274.
Siggins G.R., Roberto M., Nie Z. The tipsy terminal: presynaptic effects of ethanol. Pharmacol. Ther. (2005) 107 80-98.
Nie Z., Madamba S.G., Siggins G.R. Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms. J. Pharmacol. Exp. Ther. (1994) 271 1566-1573.
Costa E.T., Soto E.E., Cardoso R.A., Olivera D.S., Valenzuela C.F. Acute effects of ethanol on kainate receptors in cultured hippocampal neurons. Alcohol. Clin. Exp. Res. (2000) 24 220-225.
Krystal J.H., Petrakis I.L., Mason G., Trevisan L., D'Souza D.C. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol. Ther. (2003) 99 79-94.
Lovinger D.M., White G., Weight F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science (1989) 243 1721-1724.
Aistrup G.L., Marszalec W., Narahashi T. Ethanol modulation of nicotinic acetylcholine receptor currents in cultured cortical neurons. Mol. Pharmacol. (1999) 55 39-49.
Lovinger D.M., Zhou Q. Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology (1994) 33 1567-1572.
Mihic S.J. Acute effects of ethanol on GABAA and glycine receptor function. Neurochem. Int. (1999) 35 115-123.
Gonzales R.A., Job M.O., Doyon W.M. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol. Ther. (2004) 103 121-146.
Di Chiara G., Bassareo V., Fenu S. et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 47 (Suppl. 1) 227-241.
Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Rev. (1998) 28 309-369.
Cannon C.M., Bseikri M.R. Is dopamine required for natural reward? Physiol. Behav. (2004) 81 741-748.
Salamone J.D., Correa M., Mingote S.M., Weber S.M. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr. Opin. Pharmacol. (2005) 5 34-41.
Schultz W. Reward signaling by dopamine neurons. Neuroscientist (2001) 7 293-302.
Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry (2005) 162 1403-1413.
Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry (2004) 9 557-569.
Hungund B.L., Szakall I., Adam A., Basavarajappa B.S., Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J. Neurochem. (2003) 84 698-704.
Di Chiara G., Imperato A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur. J. Pharmacol. (1985) 115 131-132.
Bradberry C.W. Dose-dependent effect of ethanol on extracellular dopamine in mesolimbic striatum of awake rhesus monkeys: comparison with cocaine across individuals. Psychopharmacology (2002) 165 67-76.
Boileau I., Assaad J.M., Phil R.O. et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse (2003) 49 226-231.
Brodie M.S., Pesold C., Appel S.B. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol. Clin. Exp. Res. (1999) 23 1848-1852.
Langen B., Dietze S., Fink H. Acute effect of ethanol on anxiety and 5-HT in the prefrontal cortex of rats. Alcohol (2002) 27 135-141.
Thielen R.J., Bare D.J., McBride W.J., Lumeng L., Li T.K. Ethanol-stimulated serotonin release in the ventral hippocampus: an absence of rapid tolerance for the alcohol-preferring P rat and insensitivity in the alcohol-nonpreferring NP rat. Pharmacol. Biochem. Behav. (2002) 71 111-117.
Yan Q.S. Extracellular dopamine and serotonin after ethanol monitored with 5-minute microdialysis. Alcohol (1999) 19 1-7.
Lovinger D.M. Serotonin's role in alcohol's effects on the brain. Alcohol Health Res. World (1997) 21 114-120.
Ciccocioppo R. The role of serotonin in craving: from basic research to human studies. Alcohol Alcohol. (1999) 34 244-253.
Marinelli P.W., Quirion R., Gianoulakis C. An in vivo profile of β-endorphin in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience (2004) 127 777-784.
Marinelli P.W., Bai L., Quirion R., Gianoulakis C. A microdialysis profile of Met-enkephalin release in the rat nulceus accumbens. Alcohol. Clin. Exp. Res. (2005) 29 1821-1828.
Oswald L.M., Wand G.S. Opioids and alcoholism. Physiol. Behav. (2004) 81 339-358.
Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem. (2004) 4 39-50.
Benjamin D., Grant E.R., Pohorecky L.A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. (1993) 621 137-140.
Devaud L.L., Alele P. Differential effects of chronic ethanol administration and withdrawal on gamma-aminobutyric acid type A and NMDA receptor subunit proteins in male and female rat brain. Alcohol. Clin. Exp. Res. (2004) 28 957-965.
Diana M., Pistis M., Muntoni A., Gessa G. Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Neuroscience (1996) 71 411-415.
Rossetti Z.L., Melis F., Carboni S., Diana M., Gessa G.L. Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine. Alcohol. Clin. Exp. Res. (1992) 16 529-532.
Melis M., Spiga S., Diana M. The dopamine hypothesis of drug addiction: hypodopaminergic state. Int. Rev. Neurobiol. (2005) 63 101-154.
Brodie M.S. Increased ethanol excitation of dopaminergic neurons of the ventral tegmental area after chronic ethanol treatment. Alcohol. Clin. Exp. Res. (2002) 26 1024-1030.
Shaham Y., Shalev U., Lin L., de Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (2003) 168 3-20.
Le A.D., Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol. Ther. (2002) 94 137-156.
Hald J., Jacobsen E. A drug sensitising the organism to ethyl alcohol. Lancet (1948) 255 1001-1004.
Quertemont E. Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to alcohol abuse and alcoholism. Mol. Psychiatry (2004) 9 570-581.
Johnsen J., Stowell A., Morland J. Clinical responses in relation to blood acetaldehyde levels. Pharmacol. Toxicol. (1992) 70 41-45.
Chick J., Gough K., Wojciech F. et al. Disulfiram treatment of alcoholism. Br. J. Psychiatry (1992) 161 84-89.
Fuller R.K., Branchey L., Brightwell D.R. et al. Disulfiram treatment of alcoholism: a Veterans Administration Cooperative study. JAMA (1986) 256 1449-1455.
Hughes J.C., Cook C.C.H. The efficacy of disulfiram: a review of outcome studies. Addiction (1997) 92 381-395.
Fuller R.K., Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction (2004) 99 21-24.
Ehrenreich H., Krampe H. Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram's psychological effects. Addiction (2004) 99 25-28.
Chick J. Disulfiram: cautions on liver function; how to supervise. Addiction (2004) 99 25-28.
Bourdelat-Parks B.N., Anderson G.M., Donaldson Z.R. et al. Effects of dopamine b-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (2005) 183 72-80.
Nagendra S.N., Faiman M.D., Davis K., Wu J.Y., Newby X., Schloss J.V. Carbamoylation of brain glutamate receptors by a disulfiram metabolite. J. Biol. Chem. (1997) 272 24247-24251.
Gonzales R.A., Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J. Neurosci. (1998) 18 10663-10671.
Sinclair J.D. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. (2001) 36 2-10.
Le A.D., Poulos C.X., Harding S., Watchus J., Juzytsch W., Shaham Y. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology (1999) 21 435-444.
Liu X., Weiss F. Additive effects of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J. Neurosci. (2002) 22 7856-7861.
Monti P.M., Rohsenow D.J., Hutchison K.E. et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol. Clin. Exp. Res. (1999) 23 1386-1394.
Katner S.N., Weiss F. Ethanol-associated olfactory stimuli reinstate ethanol-seeking behavior after extinction and modify extracellular dopamine levels in the nucleus accumbens. Alcohol. Clin. Exp. Res. (1999) 23 1751-1760.
Cowen M.S. Naltrexone: preclinical data, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 49-58.
O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry (1992) 49 881-887.
Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry (1992) 49 876-880.
O'Brien C.P., Pettinati H.M., Oslin D.W. Naltrexone: clinical data, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 59-72.
Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry (1999) 156 1758-1764.
Balldin J., Berglund M., Borg S. et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol. Clin. Exp. Res. (2003) 27 1142-1149.
Srisurapanont M., Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. (2005) 8 267-280.
Gastpar M., Bonnet U., Boning J. et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J. Clin. Psychopharmacol. (2002) 22 592-598.
Kranzler H.R., Modesto-Lowe V., Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology (2000) 22 493-503.
Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A. Veterans Affairs Naltrexone Cooperative Study 425 Group, Naltrexone in the treatment of alcohol dependence. N. Engl J. Med. (2001) 345 1734-1739.
Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppasalmi K., Sinclair J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. (2001) 21 287-292.
Johnson B.A. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert. Opin. Pharmacother. (2006) 7 1065-1073.
Galloway G.P., Koch M., Cello R., Smith D.E. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychitary (2005) 5 18-28.
Garbutt J.C., Kranzler H.R., O'Malley S.S. et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomised controlled trial. JAMA (2005) 293 1617-1625.
Kranzler H.R., Wesson D.R., Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol. Clin. Exp. Res. (2004) 28 1051-1059.
Ingman K., Hagelberg N., Aalto S. et al. Prolonged central l-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology (2005) 30 2245-2253.
Sinclair J.D. Second generation opoidergic compounds: clinical data, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 125-134.
June H.L., Grey C., Warren-Reese C. et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol. Clin. Exp. Res. (1998) 22 2174-2185.
Mason B.J., Ritvo E.C., Morgan R.O. et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol. Clin. Exp. Res. (1994) 18 1162-1167.
Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry (1999) 56 719-724.
Anton R.F., Pettinati H., Zweben A. et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J. Clin. Psychopharmacol. (2004) 24 421-428.
Bachteler D., Spanagel R. Glutamatergic compounds: a perspective, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 205-216.
Dahchour A., De Witte P. Ethanol and aminoacids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog. Neurobiol. (2000) 60 343-362.
De Witte P., Littleton J., Parot P., Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS drugs (2005) 19 517-537.
Rammes G., Mahal B., Putzke J. et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology (2001) 40 749-760.
Zeise M.L., Kasparov S., Capogna M., Zieglgansberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. (1993) 231 47-52.
Harris B.R., Prendergast M.A., Gibson D.A. et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res. (2002) 26 1779-1793.
Spanagel R., Putzke J., Stefferl A., Schobitz B., Zieglgansberger W. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur. J. Pharmacol. (1996) 305 45-50.
Mayer S., Harris B.R., Gibson D.A. et al. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol. Clin. Exp. Res. (2002) 26 1468-1478.
Czachowski C.L., Legg B.H., Samson H.H. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol. Clin. Exp. Res. (2001) 25 344-350.
Spanagel R., Holter S.M., Allingham K., Landgraf R., Zieglgansberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur. J. Pharmacol. (1996) 305 39-44.
Brasser S.M., McCaul M.E., Houtsmuller E.J. Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol. Clin. Exp. Res. (2004) 28 1074-1083.
Spanagel R., Zieglgansberger W., Hundt W. Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Eur. J. Pharmacol. (1996) 305 51-56.
Spanagel R., Pendyala G., Abarca C. et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat. Med. (2005) 11 35-42.
Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction (1995) 90 1179-1188.
Quertemont E., Brabant C., De Witte P. Acamprosate reduces context-dependent ethanol effects. Psychopharmacology (2002) 164 10-18.
Bachteler D., Economidou D., Danysz W., Ciccocioppo R., Spanagel R. The effects of acamprosate and neramexane on cue-induced resinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology (2005) 30 1104-1110.
Mann K.F. Acamprosate: clinical data, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhä-user, Basel, Switzerland, 2005, pp. 85-93.
Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., Parot P. Double-blind randomized multicenter trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. (1995) 30 239-247.
Pelc I., Ansoms C., Lehert P. et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol. Clin. Exp. Res. (2002) 26 1529-1538.
Sass H., Soyka M., Mann K., Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry (1996) 53 673-680.
Whitworth A.B., Fischer F., Lesch O.M. et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet (1996) 347 1438-1442.
Chick J., Howlett H., Morgan M.Y., Ritson B. United Kingdom multicenter acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. (2000) 35 176-187.
Namkoong K., Lee B.O., Lee P.G., Choi M.J., Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. (2003) 38 135-141.
COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence - the combine study: a randomized controlled trial. JAMA (2006) 295 2003-2017.
Boothby L.A., Doering P.L. Acamprosate for the treatment of alcohol dependence. Clin. Ther. (2005) 27 695-714.
Bouza C., Angeles M., Munoz A., Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction (2004) 99 811-828.
Kranzler H.R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. (2001) 25 1335-1341.
Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res. (2004) 28 51-63.
Gual A., Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. (2001) 36 413-418.
Tupala E., Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry (2004) 28 1221-1247.
Liu X., Weiss F. Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. J. Pharmacol. Exp. Ther. (2002) 300 882-889.
Czachowski C.L., Chappell A.M., Samson H.H. Effects of raclopride in the nucleus accumbens on ethanol seeking and consumption. Alcohol. Clin. Exp. Res. (2001) 25 1431-1440.
Czachowski C.L., Santini L.A., Legg B.H., Samson H.H. Separate measures of ethanol seeking and drinking in the rat: effects of remoxipride. Alcohol (2002) 28 39-46.
Shaw G.K., Majumdar S.K., Waller S., MacGarvie J., Dunn G. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br. J. Psychiatry (1987) 150 164-168.
Shaw G.K., Waller S., Majumdar S.K., Alberts J.L., Latham C.J., Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br. J. Psychiatry (1994) 165 515-523.
Wiesbeck G.A. Dopaminergic compounds: clinical data, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 155-161.
Wiesbeck G.A., Weijers H.G., Lesch O.M., Glaser T., Toennes P.J., Boening J. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. (2001) 36 329-334.
Hutchison K.E., Swift R., Rohsenow D.J., Monti P.M., Davidson D., Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (2001) 155 27-34.
Modell J.G., Mountz J.M., Glaser F.B., Lee J.Y. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol. Clin. Exp. Res. (1993) 17 234-240.
Naranjo C.A., Dongier M., Bremner K.E. Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction (1997) 92 969-978.
Powell B.J., Campbell J.L., Landon J.F. et al. A double-bind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol. Clin. Exp. Res. (1995) 19 462-468.
Schmidt L.G., Kuhn S., Smolka M., Schmidt K., Rommelspacher H. Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26 209-217.
McDougall S.A., Hernandez R.M., Reichel C.M., Farley C.M. The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats. Psychopharmacology (2005) 178 431-439.
Weiss F. Dopaminergic compounds: preclinical data, in: Spanagel R., Mann K. (Eds), Drugs for relapse prevention of alcoholism, Birkhäuser, Basel, Switzerland, 2005, pp. 135-153.
McBride W.J., Bodart B., Lumeng L., Li T.K. Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. Alcohol. Clin. Exp. Res. (1995) 19 1420-1422.
Ginsburg B.C., Koek W., Javors M.A., Lamb R.J. Effects of fluvoxamine on a multiple schedule of ethanol- and food-maintained behavior in two rat strains. Psychopharmacology (2005) 180 249-257.
Maurel S., De Vry J., Schreiber R. 5-HT receptor ligands differentially affect operant oral self-administration of ethanol in the rat. Eur. J. Pharmacol. (1999) 370 217-223.
Roberts A.J., McArthur R.A., Hull E.E., Post C., Koob G.F. Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol. Psychopharmacology (1998) 137 25-32.
Wilson A.W., Neill J.C., Costall B. An investigation into the effects of 5-HT agonists and receptor antagonists on ethanol self-administration in the rat. Alcohol (1998) 16 249-270.
Cornelius J.R., Salloum I.M., Ehler J.G. et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1997) 54 700-705.
Kabel D.I., Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol. Clin. Exp. Res. (1996) 20 780-784.
Kranzler H.R., Burleson J.A., Korner P. et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am. J. Psychiatry (1995) 152 391-397.
Naranjo C.A., Bremner K.E., Lanctot K.L. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction (1995) 90 87-99.
Pettinati H.M., Volpicelli J.R., Kranzler H.R., Luck G., Rukstalis M.R., Cnann A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol. Clin. Exp. Res. (2000) 24 1041-1049.
Kranzler H.R., Burleson J.A., Brown J., Babor T.F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol. Clin. Exp. Res. (1996) 20 1534-1541.
Collins D.M., Myers R.D. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol (1987) 4 49-56.
George D.T., Rawlings R., Eckardt M.J., Phillips M.J., Shoaf S.E., Linnoila M. Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol. Clin. Exp. Res. (1999) 23 272-278.
Malec T.S., Malec E.A., Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol. Clin. Exp. Res. (1996) 20 853-858.
Kranzler H.R., Burleson J.A., Del Broca F.K. et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch. Gen. Psychiatry (1994) 51 720-731.
Brodie M.S., Trifunovic R.D., Shefner S.A. Serotonin potentiates ethanol-induced excitation of ventral tegmental area neurons in brain slices from three different rat strains. J. Pharmacol. Exp. Ther. (1995) 273 1139-1146.
Dewey S.L., Smith G.S., Logan J. et al. Serotoninergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. (1995) 15 821-829.
McBride W.J., Lovinger D.M., Machu T. et al. Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism. Alcohol. Clin. Exp. Res. (2004) 28 257-267.
Myers R.D., Lankford M.F. Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone. Neuropsychopharmacology (1996) 14 139-149.
Johnson B.A., Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (2000) 149 327-344.
Johnson B.A., Jasinski D.R., Galloway G.P. et al. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial. Psychopharmacology (1996) 128 206-215.
Wiesbeck G.A., Weijers H.G., Chick J., Naranjo C.A., Boening J. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Alcohol. Clin. Exp. Res. (1999) 23 230-235.
Knapp D.J., Pohorecky L.A. Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacol. Biochem. Behav. (1992) 41 847-850.
McKinzie D.L., Eha R., Cox R. et al. Serotonin3 receptor antagonism of alcohol intake: effects of drinking conditions. Alcohol (1998) 15 291-298.
Campbell A.D., McBride W.J. Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens. Pharmacol. Biochem. Behav. (1995) 51 835-842.
Johnson B.A., Roache J.D., Javors M.A. et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA (2000) 284 963-971.
Johnson B.A., Roache J.D., Ait-Daoud N., Zanca N.A., Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (2002) 160 408-413.
Kranzler H.R., Pierucci-Lagha A., Feinn R., Hernandez-Avila C. Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. Alcohol. Clin. Exp. Res. (2003) 27 1150-1155.
Sellers E.M., Toneatto T., Romach M.K., Somer G.R., Sobell L.C., Sobell M.B. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol. Clin. Exp. Res. (1994) 18 879-885.
Brady K.T., Sonne S., Anton R.F., Randall C.L., Back S.E., Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol. Clin. Exp. Res. (2005) 29 395-401.
Moak D.H., Anton R.F., Latham P.K., Voronin K.E., Waid R.L., Durazo-Arvizu R. Setraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J. Clin. Psychopharmacol. (2003) 23 553-562.
Colombo G., Serra S., Brunetti G. et al. The GABAB receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol. (2002) 37 499-503.
Besheer J., Lepoutre V., Hodge C.W. GABA(B) receptors agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology (2004) 174 358-366.
Colombo G., Agabio R., Carai M.A.M. et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I - Preclinical evidence. Alcohol. Clin. Exp. Res. (2000) 24 58-66.
Colombo G., Vacca G., Serra S., Brunetti G., Carai M.A.M., Gessa G.L. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (2003) 167 221-224.
Addolorato G., Caputo F., Capristo E., Colombo G., Gessa G.L., Gasbarrini G. Ability of baclofen in reducing alcohol craving an intake: II - Preliminary clinical evidence. Alcohol. Clin. Exp. Res. (2000) 24 67-71.
Flannery B.A., Garbutt J.C., Cody M.W. et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol. Clin. Exp. Res. (2004) 28 1517-1523.
Addolorato G., Caputo F., Capristo E. et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. (2002) 37 504-508.
Cousins M.S., Roberts D.C.S., de Wit H. GABAB receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. (2002) 65 209-220.
Bowery N.G., Hudson A.L., Price G.W. GABAA and GABA B receptor site distribution in the rat central nervous system. Neuroscience (1987) 20 365-383.
Andriamampandry C., Taleb O., Viry S. et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. (2003) 17 1691-1693.
Poldrugo F., Addolorato G. The role of γ-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol. (1999) 34 15-24.
Fadda F., Argiolas A., Melis M.R., De Montis G., Gessa G.L. Suppression of voluntary ethanol consumption in rats by gamma-butyrolactone. Life Sci. (1983) 32 1471-1477.
Fadda F., Mosca E., Colombo G., Gessa G.L. Suppression by gamma-hydroxybutyric acid of ethanol withdrawal syndrome in rats. Alcohol Alcohol. (1989) 24 447-451.
Caputo F., Addolorato G., Lorenzini F. et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. (2003) 70 85-91.
Gallimberti L., Ferri M., Ferrara S.D., Fadda F., Gessa G.L. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double blind study. Alcohol. Clin. Exp. Res. (1992) 16 673-676.
Maremmani I., Lamanna F., Tagliamonte A. Long-term therapy using GHB (sodium gamma-hydroxybutyrate) for treatment-resistant chronic alcoholics. J. Psychoactive Drugs (2001) 33 135-142.
Addolorato G., Caputo F., Stefanini G.F., Gasbarrini G. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addiction (1997) 92 1041-1042.
Chwelos N., Blewett D.B., Smith C.M., Hoffer A. Use of D-lysergic acid diethylamide in the treatment of alcoholism. Q. J. Stud. Alcohol (1959) 20 577-590.
Egli M. Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addiction Biol. (2005) 10 309-319.
Heilig M., Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol. Ther. (2006) 111 855-876.
Dorus W., Ostrow D.G., Anton R. et al. Lithium treatment of depressed and non depressed alcoholics. JAMA (1989) 262 1646-1652.
Lejoyeux M., Ades J. Evaluation of lithium treatment in alcoholism. Alcohol Alcohol. (1993) 28 273-279.
Ait-Daoud N., Malcolm R.J., Johnson B.A. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict. Behav. (2006) 31 1628-1649.
Johnson B.A. Uses of topiramate in the treatment of alcohol dependence. Expert Rev. Neurother. (2004) 4 751-758.
Johnson B.A., Ait-Daoud N., Bowden C.L. et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 361 1677-1685.
Colombo G., Serra S., Vacca G., Carai M.A.M., Gessa G.L. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol. Biochem. Behav. (2005) 81 369-380.
Cippitelli A., Bilbao A., Hansson A.C. et al. The European TARGALC Consortium. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur. J. Neurosci. (2005) 21 2243-2251.
Valdez G.R., Koob G.F. Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol. Biochem. Behav. (2004) 79 671-689.
Valdez G.R., Zorrilla E.P., Roberts A.J., Koob G.F. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol (2003) 29 55-60.
Thorsell A., Slawecki J.C., Ehlers C.L. Effects of neuropeptide Y on appetitive and consummatory behaviors associated with alcohol drinking in Wistar rats with a history of ethanol exposure. Alcohol. Clin. Exp. Res. (2005) 29 584-590.
Cano-Cebrian M.J., Zornoza-Sabina T., Guerri C., Polache A., Granero L. Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. Naunyn Schmiedebergs Arch. Pharmacol. (2003) 367 119-125.
Moncrieff J., Drummond D.C. New drug treatments for alcohol problems: a critical appraisal. Addiction (1997) 92 939-947.
COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol. Clin. Exp. Res. (2003) 27 1107-1122.
Feeney G.F.X., Connor J.P., Young R.M.D., Tucker J., McPherson A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. (2006) 41 321-327.
Kiefer F., Jahn H., Tarnaske T. et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2003) 60 92-99.
Cloninger C.R. Neurogenetic adaptive mechanisms in alcoholism. Science (1987) 236 410-416.
Higuchi S., Matsushita S., Kashima H. New findings on the genetic influences on alcohol use and dependence. Curr. Opin. Psychiatry (2006) 19 253-265.
Kenna G.A., McGeary J.E., Swift R.M. Pharmacotherapy, pharmacogenetics, and the future of alcohol dependence treatment, part 1. Am. J. Health Syst. Pharm. (2004) 61 2272-2279.